Mabwell(SH:688062) Shang Hai Zheng Quan Bao·2025-08-05 18:10Core Viewpoint - The company has announced an adjustment to its share repurchase plan, increasing the maximum repurchase price from RMB 35.00 per share to RMB 48.00 per share to ensure the smooth implementation of the plan [7][11][17]. Group 1: Share Repurchase Plan Overview - The company approved a share repurchase plan on June 26, 2025, allowing for the repurchase of its A-shares using self-owned funds and/or special loans, with a total repurchase amount between RMB 25 million and RMB 50 million [1][9]. - The repurchase period is set for 12 months from the date of board approval [1][9]. - As of July 31, 2025, the company has not yet implemented the share repurchase [2][10]. Group 2: Adjustment of Repurchase Price - The maximum repurchase price has been adjusted to RMB 48.00 per share due to the company's stock price exceeding the previous limit, which limited the implementation window [11][15]. - The adjustment is based on the company's confidence in its future development and aims to protect shareholder interests [11][16]. - The total repurchase amount remains unchanged, and the repurchase plan's other details are not affected by this adjustment [16][17]. Group 3: Company’s Business and Market Position - The company focuses on oncology and age-related diseases, with 16 core products in various stages of development, including 12 innovative drugs and 4 biosimilars [12]. - The company has several innovative drugs in critical clinical research stages, with notable achievements such as receiving multiple designations from the FDA for its drug 9MW2821 [12]. - The company has established international partnerships and is expanding its market presence, particularly in emerging markets along the Belt and Road Initiative [13].